Rochelle, Virginia (April 4, 2018) – NDA Partners Chairman Carl Peck, MD announced today that Alexander (Sander) A. Vinks, PharmD, PhD, FCP, a prominent pediatric clinical pharmacology and clinical trials expert, has joined the firm as an Expert Consultant.
Dr. Vinks is Professor of Pediatrics and Pharmacology at the University of Cincinnati, College of Medicine, Director of the Division of Clinical Pharmacology, and serves as Director of the Pediatric Clinical and Developmental Pharmacology National Institutes of Health (NIH) T32 training program at Cincinnati Children’s Hospital Medical Center. He is Co-Director of Cincinnati Children’s Genetic Pharmacology Service, and Scientific Director for pharmacy research in the Division of Patient Services. He also directs a multidisciplinary Pharmacometrics Center of Excellence, in addition to serving as an advisor on the FDA pediatric sub-committee for Pharmaceutical Science and Clinical Pharmacology.
Dr. Vinks served as the Principal Investigator of the former National Institute of Child Health and Human Development (NICHD) Pediatric Pharmacology Research Unit at Cincinnati Children’s Hospital Medical Center.
“Dr. Vinks is a prominent pediatric clinical pharmacologist with expertise in pediatric trials, clinical study design, and modeling and simulation. His knowledge and expertise will be extremely valuable to our clients developing therapies for pediatric populations. We are very pleased that he has joined NDA Partners,” said Dr. Peck.
Dr. Vinks received his PhD and MS (Doctorandus) in Pharmacy from Leiden University, The Netherlands, in addition to a PharmD from Leiden University’s Center for Bio-Pharmaceutical Sciences. He also earned a Master’s degree in Pharmacology from the University of Toronto. He is Board Certified in Clinical Pharmacology and a fellow of the American College of Clinical Pharmacology.
About NDA Partners
NDA Partners is a life sciences management consulting firm focused on providing product development and regulatory services to the pharmaceutical, biotechnology, and medical device industries worldwide. The highly experienced Principals and Premier Experts of NDA Partners include three former FDA Center Directors; the former Chairman of the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK; an international team of more than 100 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, expert consulting, high-impact project teams, and management of client product development programs.
Earle Martin, Chief Executive Officer